In the SCAN-B cohort, 18 ILCs (4.66%) were either TNBC (n = 6) or HER2-positive (n = 12) which is not unexpected since classic ILCs are predominantly ER+/Luminal-A and HER2-negative breast cancers [2]. This evidence concerns the gene ERBB2 and breast cancer.